Allergists and immunologists in 2026 serve the patients with allergic disease — the 50+ million Americans with allergic rhinitis whose nasal congestion, sneezing, and ocular symptoms require the allergen identification and immunotherapy that allergy specialist treatment provides beyond antihistamine symptom management, the 26 million Americans with asthma whose airway hyperresponsiveness and bronchospasm require the pulmonary function evaluation, trigger identification, and stepped therapy optimization that the allergy and asthma specialist delivers for the asthma control that prevents hospitalization and impaired quality of life, the food allergy population — particularly the children with peanut, tree nut, milk, and egg allergy — who require the allergen-specific IgE testing, food challenge evaluation, and oral immunotherapy that allergy specialist management provides for the food allergy diagnosis confirmation and desensitization treatment that OIT creates, the patients with urticaria, eczema, and atopic dermatitis whose inflammatory skin conditions require the allergy evaluation, patch testing, and biologic therapy that dermatology-allergy overlap conditions require from the allergy specialist's immunological perspective, the severe asthma and chronic urticaria patients who have failed standard therapy and require the biologic treatment — dupilumab (Dupixent), mepolizumab (Nucala), omalizumab (Xolair), and benralizumab (Fasenra) — that FDA-approved biologic therapy provides for the Type 2 inflammatory conditions that standard pharmacotherapy inadequately controls, and the primary immunodeficiency patients — common variable immunodeficiency, selective IgA deficiency, and specific antibody deficiency — who require the immune evaluation and IVIG replacement therapy that the clinical immunologist provides for the immune deficiency that recurrent infection creates. The US allergy and immunology market generates $8.6 billion in 2026 — in an allergic disease environment where food allergy OIT has expanded as a desensitization treatment option, where biologic therapy for allergic disease has grown with dupilumab's multi-indication approval, and where the subcutaneous immunotherapy market has sustained as the definitive allergy treatment. Practice management EHR and immunotherapy tracking platforms provide the infrastructure that virtual assistants use to coordinate the testing, immunotherapy, biologic, and billing workflows that allergy practice operations require.
The 2026 allergist practice landscape reflects the immunotherapy program management complexity creating the scheduling demand from allergy practices managing the build-up and maintenance phase subcutaneous immunotherapy schedules across large shot clinic patient populations requiring the 1-3 year build-up and 3-5 year maintenance that successful allergen immunotherapy requires, the biologic therapy prior authorization management requirement creating the insurance coordination demand from allergy practices managing dupilumab, omalizumab, and mepolizumab prior authorization with eosinophil count, IgE level, and failure of standard therapy for the biologic coverage that severe allergic disease treatment requires, and the food allergy OIT program management requirement creating the intensive protocol coordination demand from allergist practices managing the graduated escalation, home dosing, and follow-up that food allergy oral immunotherapy requires from the structured clinical program — creating the immunotherapy scheduling and biologic authorization coordination complexity that systematic virtual assistant support enables allergists to manage without allergy assessment expertise consumed by administrative coordination.
Allergist and Immunologist Practice VA Functions
Allergy evaluation and skin testing scheduling: Managing the diagnostic revenue workflow — processing allergy evaluation referrals from primary care, pediatrics, and self-referrals with allergic symptom description, prior allergy history, and insurance for comprehensive allergy evaluation scheduling, coordinating allergy skin testing scheduling with scratch test, intradermal test, and patch test panels with allergen panel preparation and antihistamine hold instruction for the organized allergy testing that accurate results require, managing spirometry and pulmonary function testing coordination for asthma evaluation with PFT scheduling and bronchodilator washout instruction for the lung function assessment that asthma diagnosis and severity classification requires, and maintaining the testing quality that the allergy practice's diagnostic foundation — where organized allergy testing creating the IgE-mediated allergen identification that immunotherapy target selection requires — demands for the evaluation management that testing coordination produces.
Subcutaneous immunotherapy shot clinic management: Supporting the primary recurring revenue workflow — managing subcutaneous immunotherapy (SCIT) build-up schedule for new immunotherapy patients with injection frequency, extract concentration progression, and reaction monitoring for the 6-12 month build-up phase that SCIT requires for adequate allergen dose, managing maintenance immunotherapy scheduling for established shot patients with monthly injection appointment, reaction observation, and dose adjustment for the 3-5 year maintenance that completed immunotherapy requires for allergen desensitization, coordinating immunotherapy extract preparation and order management with compounding pharmacy for the patient-specific allergen extract that individualized immunotherapy requires from custom allergen selection, and maintaining the immunotherapy quality that the allergy practice's shot program — where organized shot clinic with proper build-up and maintenance creating the desensitization outcome that immunotherapy investment delivers — demands for the shot clinic management that SCIT coordination produces.
Biologic therapy prior authorization and management: Managing the specialty treatment revenue workflow — coordinating dupilumab (Dupixent), omalizumab (Xolair), mepolizumab (Nucala), and benralizumab (Fasenra) prior authorization with indication documentation, eosinophil count or IgE level evidence, and standard therapy failure for the biologic authorization that severe allergic disease treatment requires from insurance coverage, managing biologic injection scheduling and monitoring for in-office biologic administration with injection site reaction monitoring and adverse event documentation for the biologic administration safety that allergy practice standards require, coordinating specialty pharmacy enrollment for self-administered biologic patients with patient assistance program and injection training for the home biologic therapy that self-administration enables, and maintaining the biologic quality that the allergy practice's severe disease program — where organized biologic management creating the clinical response that Type 2 inflammatory conditions respond to from biologic intervention — requires for the biologic management that specialty treatment coordination produces.
Food allergy evaluation and OIT coordination: Supporting the food allergy management market workflow — managing food allergy evaluation scheduling with allergen-specific IgE testing, skin prick testing, and clinical history for the food allergy diagnosis that accurate IgE sensitization assessment requires, coordinating oral food challenge scheduling for food allergy confirmation with challenge protocol, emergency medication preparation, and physician presence for the supervised challenge that food allergy decision-making sometimes requires from the definitive tolerance test, managing peanut OIT (PALFORZIA) and custom food allergy OIT program enrollment with dose escalation visits, home dosing schedule, and reaction management plan for the oral immunotherapy that peanut desensitization delivers through the structured OIT program, and maintaining the food allergy quality that the allergy practice's pediatric program — where organized food allergy management and OIT creating the life-changing outcome that peanut allergy families invest in food allergy treatment for — demands for the food allergy management that OIT coordination produces.
Drug allergy and immunodeficiency management: Supporting the specialty clinical market workflow — managing drug allergy evaluation and penicillin skin testing scheduling for patients with reported penicillin allergy requiring confirmation for the penicillin allergy de-labeling that most labeled patients prove safe for through formal allergy testing, coordinating immunodeficiency evaluation scheduling for patients with recurrent infections requiring immune workup with CBC, immunoglobulin levels, and vaccine antibody titers for the primary immunodeficiency evaluation that recurrent infection patterns trigger, managing IVIG infusion coordination for confirmed immunodeficiency patients requiring immunoglobulin replacement therapy with infusion center scheduling and insurance authorization for the IVIG access that immune deficiency treatment requires, and maintaining the immunodeficiency quality that the allergy practice's clinical immunology program — where organized immunodeficiency evaluation and IVIG management creating the comprehensive allergy-immunology service that complete specialist practice requires — requires for the drug allergy management that immunodeficiency coordination produces.
Anaphylaxis management and billing: Supporting the safety program and revenue operations workflow — coordinating anaphylaxis action plan development and auto-injector training for at-risk patients with epinephrine prescription, action plan documentation, and training appointment for the anaphylaxis preparedness that severe allergy patients require from properly equipped emergency response plans, managing EpiPen and auto-injector prior authorization for patients with anaphylaxis risk requiring cost-covered emergency epinephrine for the insurance access that life-saving auto-injector requires, preparing allergy and immunology billing with allergy testing codes 95004-95078, immunotherapy injection codes 95115-95120, biologic administration codes with J-codes, and E&M codes for accurate allergy and immunology claim submission, and maintaining the billing quality that the allergy practice's financial operations — where accurate allergy coding with immunotherapy and biologic billing creating the revenue timing that practice overhead requires — demands for the anaphylaxis management that billing coordination produces.
Allergist and Immunologist Practice Business Economics
For an allergy and immunology practice with annual revenue of $1.6 million:
- Annual allergy testing and evaluation revenue: $480,000 (primary diagnostic revenue)
- Subcutaneous immunotherapy shot clinic program: $480,000 additional annual revenue
- Biologic therapy for severe allergic disease: $384,000 additional annual revenue
- Food allergy evaluation and OIT program: $160,000 additional annual revenue
- Immunodeficiency and IVIG program: $96,000 additional annual revenue
- Allergist VA (part-time): $600–$1,200/month
- Annual net revenue impact: $38,000–$60,000
Virtual Assistant VA's allergist and immunologist practice support services provide trained allergy and immunology and healthcare administration industry VAs experienced in allergy evaluation and skin testing scheduling, subcutaneous immunotherapy shot clinic management, biologic therapy prior authorization and management, food allergy evaluation and OIT coordination, drug allergy and immunodeficiency management, anaphylaxis action plan coordination, and allergy billing — enabling board-certified allergists and immunologists to maximize allergy assessment and immunotherapy expertise without shot clinic scheduling and biologic authorization consuming physician time that allergy evaluation, oral food challenge, and immunotherapy protocol depend on.
Sources:
- ACAAI — American College of Allergy, Asthma and Immunology Practice Standards and Market Data 2025
- AAAAI — American Academy of Allergy, Asthma and Immunology Market Intelligence 2025
- FDA — Food and Drug Administration Biologics and Allergy Treatment Approvals 2025
- IBISWorld — Offices of Allergists and Immunologists in the US Industry Report 2025